tradingkey.logo
๎™

Ovid Therapeutics Inc

OVID
1.742USD
+0.272+18.48%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
123.92M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Ovid Therapeutics Inc ํšŒ์‚ฌ

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinsonโ€™s disease and Lewy body dementia (LBD).

Ovid Therapeutics Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ OVID
ํšŒ์‚ฌ ์ด๋ฆ„Ovid Therapeutics Inc
์ƒ์žฅ์ผMay 05, 2017
CEOAlexander (Margaret A)
์ง์› ์ˆ˜23
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 05
์ฃผ์†Œ441 Ninth Avenue, 14Th Floor
๋„์‹œNEW YORK
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ10001
์ „ํ™”12127764381
์›น์‚ฌ์ดํŠธhttps://ovidrx.com/
์ข…๋ชฉ ์ฝ”๋“œ OVID
์ƒ์žฅ์ผMay 05, 2017
CEOAlexander (Margaret A)

Ovid Therapeutics Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Dec 21
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Dec 21
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
RA Capital Management, LP
15.05%
Takeda Pharmaceutical Co Ltd
12.33%
Affinity Asset Advisors LLC
10.04%
Levin (Jeremy M)
5.13%
The Vanguard Group, Inc.
3.96%
๊ธฐํƒ€
53.49%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
RA Capital Management, LP
15.05%
Takeda Pharmaceutical Co Ltd
12.33%
Affinity Asset Advisors LLC
10.04%
Levin (Jeremy M)
5.13%
The Vanguard Group, Inc.
3.96%
๊ธฐํƒ€
53.49%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Hedge Fund
25.16%
Venture Capital
15.30%
Corporation
12.33%
Investment Advisor
9.59%
Investment Advisor/Hedge Fund
8.89%
Individual Investor
5.51%
Research Firm
2.77%
๊ธฐํƒ€
20.44%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
176
23.96M
33.70%
-28.43M
2025Q2
176
46.12M
64.86%
-16.45M
2025Q1
183
51.39M
72.29%
-10.07M
2024Q4
181
52.28M
73.63%
-8.46M
2024Q3
175
51.32M
72.31%
-10.19M
2024Q2
172
51.56M
72.67%
-6.81M
2024Q1
174
55.84M
78.97%
-6.53M
2023Q4
174
57.32M
81.09%
-4.46M
2023Q3
183
57.79M
81.95%
-5.02M
2023Q2
192
56.05M
79.62%
-3.53M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Takeda Pharmaceutical Co Ltd
7.53M
10.59%
--
--
Jun 30, 2025
Affinity Asset Advisors LLC
667.52K
0.94%
--
--
Jun 30, 2025
Levin (Jeremy M)
3.65M
5.14%
-20.00
-0.00%
Apr 24, 2025
The Vanguard Group, Inc.
2.64M
3.71%
-472.67K
-15.20%
Jun 30, 2025
Acadian Asset Management LLC
2.11M
2.96%
+20.29K
+0.97%
Jun 30, 2025
Renaissance Technologies LLC
2.10M
2.95%
+1.07M
+104.66%
Jun 30, 2025
Sio Capital Management, LLC
2.23M
3.14%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
1.40M
1.97%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
1.15M
1.62%
--
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis Responsible US Equity ETF
0%
๋” ๋ณด๊ธฐ
iShares Russell 2000 Growth ETF
๋น„์œจ0%
iShares Micro-Cap ETF
๋น„์œจ0%
ProShares UltraPro Russell2000
๋น„์œจ0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
๋น„์œจ0%
Proshares Ultra Russell 2000
๋น„์œจ0%
ProShares Ultra Nasdaq Biotechnology
๋น„์œจ0%
Invesco Nasdaq Biotechnology ETF
๋น„์œจ0%
Fidelity Enhanced Small Cap ETF
๋น„์œจ0%
ProShares Hedge Replication ETF
๋น„์œจ0%
Avantis Responsible US Equity ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Ovid Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Ovid Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Takeda Pharmaceutical Co Ltd๋Š” 7.53M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 10.59%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Affinity Asset Advisors LLC๋Š” 667.52K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.94%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Levin (Jeremy M)๋Š” 3.65M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 5.14%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 2.64M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.71%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Acadian Asset Management LLC๋Š” 2.11M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 2.96%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Ovid Therapeutics Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Ovid Therapeutics Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
RA Capital Management, LP
Takeda Pharmaceutical Co Ltd
Affinity Asset Advisors LLC์ž…๋‹ˆ๋‹ค.

Ovid Therapeutics Inc(OVID)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Ovid Therapeutics Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 176๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 23.96M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 33.70%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ -31.16% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Ovid Therapeutics Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Ovid Therapeutics Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™